The value of gBRCA1/2m testing for cancer risk reduction in breast and ovarian cancer is well-established.17–19 To date, researchers from the Breast Cancer Information Core (https://research.nhgri.nih.gov/bic/) have collated more than 1800 mutations in the BRCA1 gene and 2000 mutations in the BRCA2 gene.20 This collection of mutations comprises intronic changes, missense mutations, small in-frame insertions and deletions, and large rearrangements,20 and different mutations have been reported to confer varying risks for developing OC or BC. The gene discussed is BRCA1; the disease is cancer.